prostate cancer resistant to conventional treatment could be all but wiped out by a therapy that boosts the immune system , claim researchers . the us scientists used low doses of the drug oxaliplatin , which has a unique ability to activate cancer-killing immune cells in small tumours but works less well in large , aggressive tumours . lead scientist shabnam shalapour , of the university of california at san diego , said : â€˜ the presence of such b-cells in human prostate cancer calls for clinical testing of this novel therapeutic approach .